Call w/ Co-Founder
More Info

iRemedy Announces Patent Grant by US Patent Office

iRemedy Announces Patent Grant by US Patent Office

STUART, FL – (GLOBE NEWSWIRE) – June 26, 2023 – The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), an artificial intelligence powered medical supply chain solution, today announced the issuance by the United States Patent Office of a key patent for its intellectual property portfolio.

iRemedy is building a proprietary, highly scalable, intelligent supply chain management system for the medical supply industry. The Company began the project in 2018 as an effort to modernize and automate the inefficient and faulty medical supply distribution industry.

The United States Patent Office has granted Patent # 11416575 which protects a means of automated navigation for crawling the world wide web using the ParaLogue and ParaFlow languages. ParaFlow and ParaLogue are proprietary languages designed for modeling web pages and processing workflows and are protected for iRemedy’s use by additional patent applications.

The Patent application was filed by Grokit Date and has been licensed to iRemedy for exclusive use in the medical ecommerce and supply chain market. Grokit Data was founded by iRemedy’s CEO Tony Paquin, and CTO Jim Harding as a research entity working on AI technologies.

Paquin subsequently transferred his founder shares in Grokit to iRemedy, resulting in iRemedy owning approximately 40% of Grokit Data, providing a possible return on investment for use of any Grokit technology outside of healthcare.

In addition to its exclusive license of Grokit patents, and its equity investment in the Grokit portfolio, iRemedy also has four patents pending which it owns outright.

“Our technology has the potential to truly revolutionize the way medical supplies are acquired in this country. For many years healthcare providers and their patients have suffered from product shortages and exorbitant costs.,” said Tony Paquin, CEO of iRemedy. “This grant by the USPO strengthens and protects our intellectual property. These technologies are essential to the automated sourcing and offering of medical products through our platform.”

The Company expects additional patent grant announcements in 2023.

About The iRemedy Healthcare Companies
iRemedy is a trusted and reliable partner for acquiring medical supplies. They service over 10,000 healthcare provider clients nationwide. iRemedy guarantees access to verified supplies by sourcing directly from established manufacturers and distributors around the world. Their industry-leading technology and group purchasing power enable transparency and competition, driving consistently low pricing for customers every day. iRemedy is headquartered in Stuart, Florida and has offices in New York, and a distribution center in Florida. For more information, please visit www.iRemedy.com.

FOR MORE INFORMATION:
Keisha Graham
407-395-4283 | keisha@iremedy.com
OR FOLLOW US ON:

Share This Post

More To Explore

view offering circular
DISCLAIMER THESE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARDLOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS. PLEASE NOTE INVESTORS IN THIS OFFERING WILL BE CLIENTS OF THE ISSUER AND NOT DALMORE GROUP, LLC (“DALMORE”), A REGISTERED BROKER-DEALER AND MEMBER FINRA/SIPC. DALMORE’S ROLE IN THE TRANSACTION IS TO FACILITATE BACK OFFICE AND REGULATORY FUNCTIONS RELATED TO THE REGULATION A TRANSACTION, AND ACTS ONLY AS THE BROKER/DEALER OF RECORD FOR THE OFFERING LISTED. DALMORE IS NOT PROVIDING INVESTMENT ADVICE OR RECOMMENDATIONS, OR LEGAL OR TAX ADVICE. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AT: https://invest.iremedy.com/clkn/http/edgar.secdatabase.com/1886/190359623000098/filing-main.htm

7118 S. Kanner Hwy
Stuart, FL 34997

customerservice@iRemedy.com
(844) 335-3548

Copyright © 2023 iremedy All rights reserved
Invest Today

complete this form to receive our confidential investor info

Download our FREE Investor Deck

Click To Download Investor Deck